Vitro Diagnostics (VODG) stock has been on our radar for nearly two months now, and we’re glad we took note. The stock has climbed more than 30% from the $0.28 level at which we found it. Nonetheless, the gains are far from over.
In fact, a recent article and TV airing by Fox News only serves to validate the opportunity we’ve been working to bring to your attention surrounding the company’s stem cells that have been years in the making.
VODG Is A Stock To Watch After Recent Fox Coverage
In the interview Fox News outlined the fact that the company’s AlloRx stem cells resulted in a second chance at life for a critically ill, COVID-19 patient and included the observations and comments of the patients wife and daughter.
Speaking to the end result of the treatment that saved her husband’s life, his wife said, “First you have to thank God, but then you have to thank the stem cells too.” This comment was followed up by a comment from his daughter, stating that “plasma did nothing for” the 53-year husband and father of the family.
The patient was admitted to the Emergency Room in New Jersey hospital on April 1, 2020 with COVID-19 symptoms. Unfortunately for more than a month, his condition would worsen.
During his time in the New Jersey hospital, the patient was intubated and put on a ventilator, spent 36 days in a coma and experienced the beginning stages of liver and kidney failure. After being treated with convalescent plasma, the current standard of care for severely ill COVID-19 patients, the patient’s condition only continued to worsen.
With all other options failing, the FDA approved the compassionate use of AlloRx Stem Cells™, developed by VODG. The first dose of 100 million stem cells was administered on the eighth day of ventilator use. Dose two came one week later with a third dose in another week.
Soon after treatment, the patient was making his way to recovery, a recovery that the doctor attributed heavily to the AlloRx Stem Cells™ developed by VODG, when he said:
“Actually, he was in multiple organ failure. It was highly likely that he would’ve died without stem cell therapy.”
The patient is at home now doing very well in recovery from his stroke while in the ICU that resulted in left-side paralysis. He has recovered about 20% movement since discharge. He speaks well other than some residual damage from the stroke and cognitively is 100% according to his physician.
The Bottom Line
The bottom line here is simple. The patient was in very bad shape, with doctors expecting that he may have died from his condition. In an attempt to save his life, doctors did everything they knew to do to no avail. It wasn’t until the patient received treatment with Vitro’s AlloRx Stem Cells™ that he was provided with a second chance.
There’s incredible value in that.
The fact of the matter is that COVID-19 isn’t going anywhere anytime soon. Sure, vaccines are likely around the corner, but vaccines aren’t 100% effective. Some suggest that COVID-19 will become a recurring condition, much like what we see from the common cold, yet another strain of the coronavirus.
Considering this, the need for an effective treatment option couldn’t be more clear. With VODG having this case study, that its AlloRx Stem Cells™ product is effective in the treatment of severe COVID-19 symptoms, the stock is one to pay close attention to.
The fact that the company is trading with a market cap of 20 million, when biotech’s with nothing more than a hope to find a cure for COVID-19 trade in the hundreds of millions of dollars only serves to further validate the fact that VODG represents a discounted opportunity to get in on a stock with potential for tremendous growth in value.
Don’t Miss The Next Big Story
Join our free mailing list below to receive real-time news alerts.
CNA Finance and its subsidiary, Alpha Stock News, are not investment advisors or broker dealers. It is suggested that all readers do their own research or speak to a professional investment advisor before making investment decisions. CNA Finance received six thousand dollars for digital investor releations services provided to Vitro.